Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874885 · ClinicalTrials.gov registry record
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
A clinical trial of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 341
- Enrollment target
- 1
- Study location
NCT02874885: Active study of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
NCT02874885 is a study of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 341 participants, above the 94-participant average among 15 other Stage III Rectal Cancer AJCC v8 trials with a reported enrollment target (263% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02874885, a study of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 341 participants
- Enrollment target
- 1
- Study location
Study Summary
This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Researchers will also compare the level and genetic characteristics of circulating tumor elements between individuals with rectal cancer and healthy individuals to understand how they may change over time. Information from this study may help researchers better understand rectal cancer.
Primary Outcome
The proportion of patients with any CTC will be calculated with a 95% confidence interval (CI). Additionally, the actual CTC count will be plotted with a box-plot. Proportions of patients with 2 or more, and 3 or more CTCs will be calculated. Will also explore correlations between the presence of 1 or more CTC and primary tumor characteristics using Chi-Squared or Fischer's exact tests as appropriate.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2013-09-05 |
| Est. Completion | 2027-04-30 |
What the registry record for NCT02874885 still lists
NCT02874885 is an observational study that tracks outcomes without assigning an intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, above the 94-participant average among 15 other Stage III Rectal Cancer AJCC v8 trials with a reported enrollment target (263% higher).
The record links to 10 conditions, with Stage III Rectal Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT02874885 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02874885 about?
NCT02874885 is a clinical study titled "Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer". This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Researchers will...
What is the current status of trial NCT02874885?
This trial is currently active not recruiting. The enrollment target is 341 participants. The study started on 2013-09-05. Estimated completion is 2027-04-30.
What conditions does trial NCT02874885 study?
This clinical trial studies the following conditions: Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Metastatic Rectal Adenocarcinoma, Stage IIIC Rectal Cancer AJCC v8.
What interventions are being tested in trial NCT02874885?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT02874885?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02874885 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Rectal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02874885's enrollment target sits among peer trials
341 2nd of 15 the highest of 15 other Stage III Rectal Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Rectal Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
RECRUITING · Early Phase 1
-
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
RECRUITING · Phase 1
-
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
RECRUITING · Early Phase 1
-
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
RECRUITING
-
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI